Viewing Study NCT06977893


Ignite Creation Date: 2025-12-25 @ 1:20 AM
Ignite Modification Date: 2026-01-01 @ 1:36 AM
Study NCT ID: NCT06977893
Status: RECRUITING
Last Update Posted: 2025-05-18
First Post: 2025-05-12
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
Sponsor: First Affiliated Hospital of Zhejiang University
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None HR+/HER2- Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Breast cancer View
None Toripalimab View
None Adjuvant Chemotherapy View
None Immunotherapy View
None HR-positive HER2-negative View